Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Association for Cancer Research (AACR)
American Association for Cancer Research (AACR)
The
American Association for Cancer Research
(
AACR
) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 42,000 members in over 120 countries. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.
Year in Review
Phase 2 Study of Osimertinib + Oleclumab in Progressive T790M-Negative EGFR-Mutated NSCLC
AACR & ASCO 2021 – Midyear Review
The combination of a novel CD73 inhibitor, oleclumab, and osimertinib was well tolerated and effective in patients with advanced
EGFR
-mutated and T790M-negative non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Phase 1 Study of Telisotuzumab Vedotin in Patients with c-Met–Mutated Advanced NSCLC
AACR & ASCO 2021 – Midyear Review
Telisotuzumab vedotin (teliso-V), an anti–c-Met antibody conjugated with a tubulin inhibitor payload, is active in selected patients with advanced c-Met–positive non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab in Advanced NSCLC
AACR & ASCO 2021 – Midyear Review
With 2 years’ minimum follow-up, first-line use of nivolumab, ipilimumab, and chemotherapy offers durable survival relative to chemotherapy alone in patients with advanced non–small-cell lung cancer.
Read More ›
Year in Review
Rucaparib in High Genomic Loss of Heterozygosity and/or BRCA1/2-Mutated NSCLC (Lung-MAP Sub-Study, S1900A)
AACR & ASCO 2021 – Midyear Review
As a marker of homologous recombination deficiency, genomic loss of heterozygosity does not predict efficacy of rucaparib in advanced non–small-cell lung cancer (NSCLC).
Read More ›
Year in Review
Four-Year Update from CheckMate-227 Study of Nivolumab plus Ipilimumab in Advanced NSCLC
AACR & ASCO 2021 – Midyear Review
After 4 years’ follow-up, nivolumab combined with ipilimumab provides durable, long-term survival benefit compared with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) regardless of PD-L1 expression.
Read More ›
Year in Review
Racial Disparities in Biomarker Testing and Clinical Trial Enrollment in NSCLC
AACR & ASCO 2021 – Midyear Review
Rates of comprehensive biomarker testing and clinical trial participation were significantly lower for black patients with advanced non–small-cell lung cancer (NSCLC) in the United States compared with white patients.
Read More ›
Year in Review
Capmatinib in MET Exon 14–Mutated Advanced NSCLC (GEOMETRY Mono-1 Study)
AACR & ASCO 2021 – Midyear Review
Capmatinib offers deep and durable responses with a manageable toxicity for patients with
MET
exon 14–mutated advanced profile non–small-cell lung cancer (NSCLC) regardless of line of therapy.
Read More ›
Videos
Year in Review
Combination Therapies and New Molecular Targets—Presentations from AACR 2021
By
David Spigel, MD
AACR & ASCO 2021 – Midyear Review
Dr David Spigel reviews potentially practice-changing data on EGFR-TKI combination therapies in NSCLC, new approaches to advanced NSCLC and CNS involvement, and hopeful early data with novel targeted agents.
Read More ›
Videos
Year in Review
Practice-Changing Data in NSCLC from ASCO 2021
By
Mark A. Socinski, MD
AACR & ASCO 2021 – Midyear Review
Dr Mark Socinski provides his insights into important new data on
EGFR
inhibitors and immunotherapy in the first-line setting for NSCLC.
Read More ›
Videos
Year in Review
Exciting New Data Presented on NSCLC at AACR 2021
By
David Spigel, MD
AACR & ASCO 2021 – Midyear Review
Dr David Spigel discusses key presentations on immunotherapy and targeted therapy in the neoadjuvant and adjuvant settings in NSCLC.
Read More ›
Page 2 of 3
1
2
3
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us